@article {PULA4059, author = {BARTOSZ PULA and ELZBIETA ISKIERKA-JAZDZEWSKA and MONIKA DLUGOSZ-DANECKA and AGNIESZKA SZYMCZYK and MAREK HUS and AGNIESZKA SZEREMET and JOANNA DROZD-SOKOLOWSKA and ANNA WASZCZUK-GAJDA and JAN M. ZAUCHA and JADWIGA HOLOJDA and WERONIKA PISZCZEK and PAWEL STECKIEWICZ and MALGORZATA WOJCIECHOWSKA and MICHAL OSOWIECKI and WANDA KNOPINSKA-POSLUSZNY and MAREK DUDZINSKI and DARIA ZAWIRSKA and EDYTA SUBOCZ and JANUSZ HALKA and ANDRZEJ PLUTA and RYSZARD WICHARY and BEATA KUMIEGA and BOZENA K. BUDZISZEWSKA and WOJCIECH JURCZAK and EWA LECH-MARANDA and KRZYSZTOF GIANNOPOULOS and TADEUSZ ROBAK and KRZYSZTOF JAMROZIAK}, title = {Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study}, volume = {40}, number = {7}, pages = {4059--4066}, year = {2020}, doi = {10.21873/anticanres.14403}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: To study the long-term clinical efficacy and tolerability of ibrutinib monotherapy in real-world relapsed and refractory chronic lymphocytic leukemia (RR-CLL) patients outside clinical trials. Patients and Methods: Clinical data of 171 RR-CLL patients treated with ibrutinib were collected within the observational study of the Polish Adult Leukemia Study Group. Results: Median patient age was 64 years. Patients were pretreated with 3 (1-10) median lines of therapy, while 42 (24.6\%) had 17p deletion. The median observation time was 40 months (range=1-59 months), while median ibrutinib monotherapy reached 37.5 months (range=0.4-59.2 months). Response was noted in 132 (77.2\%) patients. The estimated 5-year progression-free survival (PFS) and overall survival (OS) rates were 61.1\% (95\%CI=49.3-70.9\%) and 56.8\% (95\%CI=45.6-66.6\%), respectively. At the time of analysis 97 (56.7\%) remained under ibrutinib monotherapy. Conclusion: Ibrutinib is clinically effective and tolerable as a monotherapy in real-world RR-CLL patients.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/40/7/4059}, eprint = {https://ar.iiarjournals.org/content/40/7/4059.full.pdf}, journal = {Anticancer Research} }